Physician profile
Cindy Tobin
NPI 1336161561
$599.34
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $59.16 · 2021: $58.44 · 2022: $158 · 2023: $63.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $63.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $63.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $134.56 | 2019 | |
| Amag Pharmaceuticals, INC. | $78.78 | 2019-2020 | |
| Aspira Women'S Health INC | $75.10 | 2020-2021 | |
| Therapeuticsmd, INC. | $72.91 | 2019-2022 | |
| Exeltis, USA INC. | $48.88 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $46.10 | 2022 | |
| Hologic Sales and Service, LLC | $38.29 | 2023 | Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $25.25 | 2023 | |
| Smith+Nephew, INC. | $22.74 | 2020 | |
| Duchesnay USA Incorporated | $20.14 | 2019 | |
| Coopersurgical, INC. | $19.04 | 2022 | |
| Abbvie INC. | $17.55 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Tobin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.